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Preface 
 
Project context  
In countries such as Australia, Canada and the United Kingdom, government reimbursement 
of pharmaceutical compounds requires certain HTA guidelines to be met. One of these 
guidelines includes the criteria of cost-effectiveness of a new drug relative to standard of 
care. Health economic models used to estimate the incremental cost-effectiveness ratio 
require lifetime estimates of survival to accurately capture any Quality Adjusted Life Year 
gain or loss. Clinical trials which are used to inform health economic models have limited 
observable survival outcomes. This is due to the design of trials needing to satisfy only the 
scope of regulatory requirements of safety and efficacy. The consequence of this approach 
leads to clinical trial results to have a number of censored observations. This leads to 
extrapolated survival estimates beyond the period of observation. Currently, most methods 
employ classic parametric modelling techniques to estimate the model data generating 
process, where after a predicted survival curve is used to extrapolate the observed survival 
trajectory. However for certain contexts, the use of classic parametric survival modelling 
methods can lead inaccurate estimates of the survival trajectory in patients who are treated 
with curative intent. To account for deficiencies in current modeling methods,  new 
parametric survival techniques are needed. One such technique is the use of mixture-cure 
models. In this thesis I explore the use of this technique in the context of a randomized 
clinical trial in patients diagnosed with stage III colorectal treated with curative intent. 
   
Student’s role:  My role in this thesis has been to learn and apply the techniques of 
parametric survival modelling for both the classic parametric and mixture-cure models. For 
the classic parametric survival and hazards models, an already built SAS macro was available 
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to be used. The macro was developed internally within the MORSE Statistics Unit. I used this 
macro to run specific parametric survival and hazard functions and curves, but also ran 
checks (for my own understanding) using the PROC LIFEREG and PROC LIFETEST 
programs. For the mixture-cure model, a colleague who is part of the MORSE group (HTA 
Statistician Federrico Felizi) developed the method for Roche HTA submissions. Federrico 
guided my understanding and assisted by developing a basic model SAS framework based on 
more complex code developed in R. I used the SAS framework for estimating predicted 
survival based on a mixture-cure model. Federrico also provided the background survival 
trajectory for the clinical trial population used in the calculation of the mixture-cure model 
(This is discussed in detail in the methods section). I lead the statistical analysis, model 
selection, extrapolation and interpretation of the results.  
 
Reflections and learnings  
Communication: I met regularly with the HTA statistician who developed the mixture-cure 
model for HTA submissions (Federrico Felizzi). Part of my learning required interpretation 
and re-communicating the key ideas and techniques to ensure I was able to apply this 
approach. I also discussed key findings and interpretation of both classic parameteric and the 
mixture-cure models within the context of applying to survival extrapolation with my onsite 
supervisor (Pierre).   
 
Work patterns/planning: Prior to commencing the project I was able to arrange 1 day a week 
with my workplace supervisor to work on the thesis. He was very supportative, as were my 
other colleagues, as is the general approach to further education in Roche. Much of the work 
required my time to be spent on weekends and evenings on developing my knowledge of key 
concepts and ideas behind classic parametric and mixture-cure survival and hazard functions .  
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Statistical principles: ‘Prediction’ is a key feature of this thesis. My aim in this project was to 
derive a valid set of parametric survival models based on an initial set of trial data (data-cut), 
or training data, then test the best-fit models to determine how well the predicted survival 
reflects the observed survival from the same trial final data-cut. In contrast to most of the 
coursework on survival analysis, this project has allowed me to develop an understanding of 
parametric models and the methods of identifying the data generating process that best fits 
proposed parametric forms. The limitations of this thesis were the limited quantification of 
statistical uncertainty and lack of external validity with survival predictions. To date, methods 
I have used in this project do not fully cover quantification of uncertainty in prediction 
estimates other than those derived from sampling variability used to construct 95% 
confidence intervals for non-parametric survival curves. If given more time I would like to 
have utilized Monte Carlo sampling of estimated variance around the parameter estimates of 
the parametric functions to explore the range and direction of the predicted survival 
trajectory.  To address the question of external validity, the next step would be to compare the 
predicted survival estimates with cancer registry data both with and without a similar set of 
patient characteristics to the clinical trial population.   
 
Statistical methods: To achieve the project objective of identifying the most accurate 
extrapolated survival trajectory, I applied the methods of both classic parametric and mixture-
cure survival modelling.  This approach presented a challenge as it was beyond the scope of 
the general BCA coursework of survival analysis. To undertake the project I needed to extend 
my knowledge by understanding how parametric and mixture-cure model parameters were 
derived and apply these methods to derive predicted survival curves. Much of the mixture-
cure work was unfamiliar. The general ideas of cure and non-cure in the mixture-cure model 
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were able to be understood, but the derivation of the parameters required to build a survival 
model required an understanding of new techniques I was not familiar with. This included the 
use of SAS code to maximize the log-likelihood to estimate parameters, in particular the step-
wise approach to re-estimate parameters based on external data sources (SEER) and applying 
these to a clinical trial dataset to estimate the predicated and extrapolated survival curves. In 
addition to the new ideas of mixture-cure models, I needed to develop an understanding of 
model fitting to observed data as recommended by NICE guidance. In this respect, I learnt 
about the use and interpretation of the shape of the log-cumulative survival, the empirical 
estimates of the hazard rates and how they may relate to specific parametric hazard functions, 
and the use (and limitations) of AIC.   
 
Statistical computing: One of the major challenges in undertaking this project was the use of 
new computer software and systems. For the BCA coursework, I learnt and applied STATA. 
However for this project, I needed to use SAS. This was a software I  had not used for more 
than 10 years. In addition, much of the use of SAS involved writing the code in separate 
software, ‘Nedit’, saving this script, and running data and SAS program from an external 
server. This was a key challenge that required time to adapt to a new interface and system.   
 
Teamwork 
Working with team members: Working with other statisticians was key for this thesis to being 
completed. Many of the statisticians were able to provide feedback on how certain methods 
were undertaken, and the reason for their use in the context of cost-effectiveness models. A 
key area in working with team members was in developing the mixure-cure model. I was able 
to negotiate specific aspects of the model that I could learn and develop, while my colleague 
who developed the mixture-cure model for Roche HTA submissions was able to provide data 
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for aspects related to background mortality (a component of the calculation of predicted 
survival using the mixture-cure model). This component is part of the calculation to estimate 
survival for mixture-models. I was also able to obtain feedback from my colleagues regarding 
notation for the mixture-cure model and interpretation of results.  
 
Working within timelines: The main timeline for the project was to complete the project 
before the due date. Where needed, I was able to devote more time to the project where there 
was a lull in other aspects of my work. I was able to obtain timely feedback from requests 
from my supervisor and colleagues. Given the challenging workload for my supervisor and 
colleagues, I had to adapt feedback for specific analyses at selected timepoints that suited 
their needs. Hence flexibility was a skill I needed to develop for the project to be complete.   
 
Ethical considerations 
The clinical trial data used in this thesis was approved by FDA and EMA at the time of 
regulatory approval. The key ethical consideration for this project was to follow scientific 
principle of methodological validity. My approach was to develop a best fit parametric model 
based on the trial’s initial datacut. To ensure my method was valid, I did not re-estimate the 
prediction based on further assessment of the final data-cut. This would be unethical and 
undermine the validity of the approach. In writing up the results, I undertook the approach 
that, whether a good fit or not, the pros and cons of the best selected model should be 
discussed relative to other parametric survival model options.  
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Introduction 
One of the key features of the Health Technology Assessment (HTA) framework is the need 
to include a cost-effectiveness analysis (CEA) of a new intervention [1]. This type of 
evaluation compares the added benefit and associated costs of a new intervention relative to 
the current standard of care. To fulfill a CEA one needs estimates around the costs and 
benefits of the interventions being compared. More often than not, the costs and benefits are 
assessed across a patient’s lifetime [2]. However, in the context of clinical trials, the resource 
requirements for long term evaluation of costs and benefits are prohibitive and not required 
by regulatory authorities. Consequently, to satisfy the needs of HTA bodies, survival 
outcomes modelled in CEA need to be extrapolated beyond observed survival (observed in 
clinical trials).  
 
In general, the extrapolation of survival outcomes is based on fitting an appropriate 
parametric survival model to the observed clinical trial data [2]. The choice of parametric 
models used to fit the distribution around a particular set of survival data can include an 
exponential, Weibull, log-logistic model, Gompertz, or a log-normal model [3]. However, 
when imposing one of these model structures onto a set of survival data, certain criteria need 
to be used to evaluate the fit of the model to the observed data. These assessments include 
statistical testing (AIC, BIC, sum of squared deviations, Martigale residuals), visual 
inspection, clinical validity, and the potential to use external data (if available) [4]. However, 
even with these various assessments, there is the possibility that the ‘best’ fit model does not 
plausibly follow the long term observed outcomes [5].  
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Mixture-cure models provide an alternative approach to the classic set of parametric models 
[6]. In certain treatment contexts classic parametric models may not accurately reflect 
survival outcomes over longer observation periods. Such treatment contexts include adjuvant 
treatment where there is curative intent. For patients diagnosed with non-metastatic staged 
disease, often the choice of treatment involves excision or organ removal, followed by 
adjuvant chemotherapy and or radiotherapy. For some patients, the residual cancers may not 
be eliminated, and hence will likely follow an accelerated failure time, which may be 
captured accurately using standard parametric models. However, for other patients where the 
disease is cured, standard parametric models may overestimate the rate of failure over longer 
periods of observation. Consequently, patients who fall into the cured category will follow a 
survival trajectory that follows the population background mortality. Mixture-cure survival 
models provide a platform that takes into account the survival trajectory of both cured and 
non-cured population.   
 
One context in which mixture-cure survival models can be compared with standard 
parametric survival models is in the randomized clinical trial setting. Large scale randomized 
clinical trials which evaluate the safety and efficacy of pharmacological compounds have 
several points of ‘inspection’ of clinical trial data (datacuts) by a data monitoring committee. 
The initial datacut provides an opportunity to assess which parametric model fits best to the 
data generating process. At this initial stage there are a limited number of outcomes due to 
the shorter period of observation. At the final datacut there are likely to be more observed 
outcomes. It is the latter data set that provides an opportunity to assess the predictive fit of the 
initial standard parametric or mixture-cure model.  
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The XACT study is a randomized clinical trial designed to compare the safety and efficacy of 
adjuvant oral fluoropyrimidine capecitabine to that of bolus 5-fluorouracil and leucovorin (5-
FU/LV) in patients diagnosed with stage III colon cancer [7]. 1987 patients were enrolled in 
164 centres around the world between 1999-2001. The primary and secondary endpoints of 
the study were disease free (DFS) and overall survival. The study was designed to assess the 
equivalence of DFS of capecitabine to that of bolus 5-FU/LV. In the cost-effectiveness 
analysis used for the HTA submission for drug reimbursement,  survival outcomes associated 
with capecitabine were based on an initial data-cut of the trial extrapolated using certain 
parametric survival assumptions. However, to date it remains uncertain as to how well the 
parametric survival curves fitted to observe survival outcomes over the longer term.  
 
My aims in this thesis were therefore to: 
1. Fit a set of parametric and mixture cure models to overall survival in patients 
diagnosed with stage III colorectal cancer treated with curative intent, based on an 
initial data-cut of the XACT clinical trial.  
2. Assess which set of parametric models (standard and mixture-cure) best fits the 
overall survival, based on an initial data-cut of the XACT clinical trial.   
3. Evaluate how well the selected best fitting parametric models predicts observed 
overall survival based on the final datacut of the XACT clinical trial. 
4. Extrapolate the best fit parametric and mixture cure survival model beyond the 
observation period, over the long-term.  
 
13 
 
Materials and Methods 
Data source 
The XACT trial is a randomized clinical trial with several datacuts. All data had been 
cleaned, so no additional data cleaning was necessary. The first datacut on outcomes (file: 
i66001d) was made available based on a median follow-up time of 2.98 years (min: 0.003 yrs 
– max: 5.41 years), while the final datacut on outcomes (file: i66001h) was made available 
after a median follow-up time of 5.20 years (min: 0.003 yrs – max: 8.63 years).  For each 
datacut, patient outcomes were recorded as having one of the following events: progressive 
disease (relapse of recurrence), death, or no event. A ‘progression’ or ‘death’ event were 
recorded as a ‘1’, otherwise patient events were censored ‘0’ (no event). For a particular 
datacut, a specific point in time was used define the time-to-event or censoring (no event 
during time follow-up interval). Therefore a failure indicator for person ′ 𝑖 ′ was defined as 
𝛿𝑖 = 1 if 𝑇𝑖 ≤ 𝑈𝑖 or 𝛿𝑖 = 0 if 𝑇𝑖 > 𝑈𝑖, where T and U are time-to-event and observation time, 
respectively. Observation time referring to date of initiation of treatment until last date of 
observation, Similarly, a censoring indicator for person ′ 𝑖 ′ was defined as 𝑐𝑖 = 0 if 𝑇𝑖 ≤ 𝑈𝑖 
or 𝑐𝑖 = 1 if 𝑇𝑖 > 𝑈𝑖. All statistical analysis was conducted using SAS 9.4.  
 
Parametric survival models  
Parametric survival models can be defined as mathematical expressions of time-to-event 
phenomena that follow a particular probability distribution. These include exponential, log-
normal, log-logistic, gamma, to name a few [3, 8]. The mathematical expression for these 
distributions need to be compared with observed time-to-event outcomes to determine which 
distribution is likely to be reflected in the observed data. The expressions for distributions 
used for comparing observed time-to-event outcomes include the survival function 𝑆(𝑡), the 
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hazard function ℎ(𝑡), and the cumulative hazard function 𝐻(𝑡). The survival function is 
expressed as follows: 
𝑆(𝑡) = Pr(𝑇 > 𝑡) 
= ∫ 𝑓(𝜇)𝑑𝜇
∞
𝑡
 
= 1 − 𝐹(𝑡) 
 
The definition of the survival function is the probability the random variable 𝑇 (a random 
variable that can take on any number greater than or equal to 0) is greater than some the 
observed value t. The function 𝑓(𝜇) represents the probability density function of the random 
variable, such that the probability of a specific value of the random variable 𝑇 is 𝑓(𝑡). The 
function 𝐹(𝑡)  is the cumulative probability of failure, such that 𝐹(𝑡) = Pr(𝑇 ≤ 𝑡).  
 
The hazard function, defined as the instantaneous rate of failure, is also called a conditional 
failure rate. This is because the failure rate is based on the probability of failure in a particular 
time interval given one has not had a failure before the beginning of the time interval. This 
can be expressed as: 
 
ℎ(𝑡) =  lim
△𝑡→0
Pr([𝑡 + △ 𝑡] > 𝑇 > [𝑡|𝑇 > 𝑡])
△ 𝑡
 
=
𝑓(𝑡)
𝑆(𝑡)
 
 
Finally, the cumulative hazard function can be defined as the number of failure times on 
average one would observe during a particular interval. This is expressed as: 
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𝐻(𝑡) = −ln [𝑆(𝑡)] 
 
Modelling parametric survival models to XACT clinical trial data 
 In this analysis I utilized a pre-programmed SAS macro to identify the best fitting parametric 
survival curve for each datacut of the XACT clinical trial. The macro presented in the 
appendix was developed by the MORSE team at Hoffman-La Roche’s. For the purposes of 
the macro the clinical trial data is divided into two separate tables, one reflects participants’ 
demographic details (fixed) and the other reflects efficacy, or outcomes, of participants 
(datacuts). It is the efficacy dataset that is updated. The first datacut  (file: i66001d) is used to 
estimate the best fitting parametetric curve for the data generating process. The final datacut 
(file: i66001h) is used as the ‘gold standard’ to compare how well the best fitting parametric 
survival predicts observed outcomes (death).  
 
Built into the macro are a series of parametric and non-parametric functions. For all analyses 
I define the covariate 𝑥 as a dichotomous variable for whether a participant received the 
control drug (5U+Leucovorin) 𝑥 = 0, or the intervention drug (Capecitabime) 𝑥 = 1. The 
first parametric function that is modelled on the observed data is based on the exponential 
distribution, For each treatment arm the hazard and survival functions are calculated as: 
 
ℎ(𝑡𝑖|𝑥 = 1) = exp (−[𝛽0 + 𝛽1𝑥]) 
𝑆(𝑡𝑖|𝑥 = 1) = exp [− exp(−[𝛽0 + 𝛽1𝑥]) ∗ 𝑡𝑖] 
 
ℎ(𝑡𝑖|𝑥 = 0) = exp (−𝛽0) 
𝑆(𝑡𝑖|𝑥 = 0) = exp [− exp(−𝛽0) ∗ 𝑡𝑖] 
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Where 𝛽0 is the intercept (the coefficient value of the control arm, 5U+Leucovorin) while the 
𝛽1 is the coefficient value for the effect of the intervention arm (Capecitabime) on death.  For 
data generating process that follow a Weibull distribution, the hazards and survival 
functions are expressed as: 
 
ℎ(𝑡𝑖|𝑥 = 1) = (
1
𝑝
) ∗ exp (−
(𝛽0 + 𝛽1𝑥)
𝑝
) ∗ 𝑡𝑖
(
1
𝑝−1)
 
𝑆(𝑡𝑖|𝑥 = 1) = exp [− exp(−
(𝛽0 + 𝛽1𝑥)
𝑝
)∗ 𝑡𝑖
1
𝑝 [ 
 
ℎ(𝑡𝑖|𝑥 = 0) = (
1
𝑝
) ∗ exp (−
𝛽0
𝑝
) ∗ 𝑡𝑖
(
1
𝑝−1)
 
 
𝑆(𝑡𝑖|𝑥 = 0) = exp [− exp (−
𝛽0
𝑝
)∗ 𝑡𝑖
1
𝑝] 
 
The additional parameter 𝑝 is the scale parameter, such that values of the scale parameter 
determine the hazard function shape. If the scale is 𝑝 = 1, then the above expression reduces 
to the exponential distribution described above. A data generating process for the log-normal 
distribution has the following hazard and survival function characteristics for each treatment 
arm: 
 
ℎ(𝑡𝑖|𝑥 = 1) =
𝜑 ∗ (
[log(𝑡𝑖) − (𝛽0 + 𝛽1𝑥)]
𝑝 )
𝑡𝑗 − (𝑡𝑗 ∗ 𝜑) ∗ (
[log(𝑡𝑖) − (𝛽0 + 𝛽1𝑥)]
𝑝 )
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𝑆(𝑡𝑖|𝑥 = 1) = 1 − 𝜑 ∗ (
[log(𝑡𝑖) − (𝛽0 + 𝛽1𝑥)]
𝑝
) 
 
ℎ(𝑡𝑖|𝑥 = 0) =
𝜑 ∗ (
[log(𝑡𝑖) − 𝛽0]
𝑝 )
𝑡𝑗 − (𝑡𝑗 ∗ 𝜑) ∗ (
[log(𝑡𝑖) − 𝛽0]
𝑝 )
 
 
𝑆(𝑡𝑖|𝑥 = 0) = 1 − 𝜑 ∗ (
[log(𝑡𝑖) − 𝛽0]
𝑝
) 
 
where the 𝜑 is the cumulative distribution function of the standard normal distribution. The 
data generating process for the log-logistic distribution has the following hazard and 
survival function: 
 
ℎ(𝑡𝑖|𝑥 = 1) =
(
1
𝑝 ∗ exp (
−[𝛽0 + 𝛽1𝑥]
𝑝 ) ∗ 𝑡𝑖
(
1
𝑝−1))
(1 + exp (
−[𝛽0 + 𝛽1𝑥]
𝑝 ) ∗ 𝑡𝑖
1
𝑝)
 
 
𝑆(𝑡𝑖|𝑥 = 1) =
1
(1 + exp (
−[𝛽0 + 𝛽1𝑥]
𝑝 ) ∗ 𝑡𝑖
1
𝑝)
 
 
ℎ(𝑡𝑖|𝑥 = 0) =
(
1
𝑝 ∗ exp (
−𝛽0
𝑝 ) ∗ 𝑡𝑖
(
1
𝑝−1))
(1 + exp (
−𝛽0
𝑝 ) ∗ 𝑡𝑖
1
𝑝)
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𝑆(𝑡𝑖|𝑥 = 0) =
1
(1 + exp (
−𝛽0
𝑝 ) ∗ 𝑡𝑖
1
𝑝)
 
 
These specified functions have been adapted from an internal Roche document title ‘Stem 
Macro Derivations’. The macro is based on pre-specified SAS procedural codes including 
PROC LIFREG, and PROC LIFETEST.  
 
General criteria to assess parametric survival curve fit  
To date no fixed standard exists to determine the best fitting parametric curve. The National 
Institute for Health and Clinical Excellence (NICE) has provided a technical report to guide 
economic evaluations submissions of health technology interventions that require 
extrapolated survival curves for clinical trial patient level data [2]. 
 
The key approaches outlined by NICE to guide assessment of suitability of survival models 
include visual inspection, log-cumulative hazard plots, and AIC/BIC tests. The visual 
inspection approach entails exploring how well a parametric curve follows a non-parametric 
(Kaplan-Meier) survival curve of the time-to-event data. However, caution needs to be taken 
with this approach where there are points of heavy censoring along certain parts of the curve, 
in particular the tail ends. The parametric curve may be appropriate for certain segments, but 
not for others.   
 
Log-cumulative hazard plots provide insight into how the hazard occurs over time. Different 
parametric functions described above present hazards that can be either constant 
(exponential), monotonic (Weibull, Gompertz) or non-monotonic (log-logistic, log-normal, 
gamma). The use of a log-cumulative hazard, which is based on a log of the –log of the 
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survival function over the log of time can assist in describing the nature of the hazards. The 
changing nature of the gradient of the log-cumulative hazard curve can assist in deciphering 
the nature of the hazard.  
 
An alternative approach to estimate the hazard shape is to plot an estimate of the hazard using 
a kernel smoothing estimator. The approach applies a kernel weight to the differences in the 
cumulative hazard estimate between event times. An approximation for the cumulative 
estimate is the Nelson-Aalen estimator: 
 
?̂?(𝑡) =  ∑ 𝑑𝑗/𝑛𝑗
𝑗|𝑡𝑗<𝑡
 
Where 𝑑𝑗is the number of failures at time 𝑗, and 𝑛𝑗  is the number at risk at 𝑗, where the sum 
of each event at 𝑡𝑗 is upto to 𝑡. The estimate of the hazard function at each event time is: 
 
ℎ̂(𝑡) = 𝑏−1∑𝐾𝑡
𝐷
𝑗=1
(
𝑡 − 𝑡𝑗
𝑏
) ∗ Δ?̂?(𝑡𝑗) 
 
Where 𝑏 is the bandwidth, 𝐷 is the total number of event times 𝑗 = 1…𝐷, 𝐾𝑡 is some kernel 
function and Δ?̂? = Δ?̂?(𝑡𝑗) − Δ?̂?(𝑡𝑗−1).  
 
However, caution needs to be taken with this approach with different kernel smoothing 
estimators and their associated bandwidths. Broadly speaking, too broad a bandwidth used in 
a kernel estimator can lead to bias in the interpretation of the curve (underfitting), whereas 
too narrow bandwidth can lead to extreme variance (overfitting) displaying a more jagged 
curve. In the Roche macro, the choice of macros are Uniform, Epanechnikov, and biweight 
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kernel smooth estimators. The Uniform kernal is defined as 𝐾(𝑢) = 1/2, the Epanechnikov 
is defined as  𝐾(𝑢) = (
3
4
) ∗ (1 − 𝑢2),  while the Biweight is defined as 𝐾(𝑢) =
15
16
∗
(1 − 𝑥2)2.  Where 𝑢 is(
𝑡−𝑡𝑗
𝑏
) in this context. The choice of bandwidth is based on a SAS 
preprogrammed golden section search algorithm. The algorithm identifies a bandwidth that 
minimizes the mean integrated squared error for the event times. This is defined as: 
 
𝑀𝐼𝑆𝐸(𝑏) = 𝐸 [∫ (ℎ̂(𝑡, 𝑏) − ℎ̂(𝑡))
2
𝜏𝑈
𝜏𝐿
] 
 
Where the expectation is over various values of ℎ(𝑡) integrated at selected intervals of times 
of events (𝜏𝐿 𝑡𝑜 𝜏𝑈).   
 
The final key approach that is presented for assessing the fit of a parametric survival model is 
the use of Akaike’s Information Criteria (AIC) and the Bayesian Information Criteria (BIC).  
The calculation of these estimates are: 
 
𝐴𝐼𝐶 = 2𝐾 − 2ln (𝐿) 
 
𝐵𝐼𝐶 =  −2 ln(𝐿) + 𝐾 ∗ ln (𝑛) 
 
Where 𝐾 is the number of parameters used in the parameteric equation, 𝐿 is the maximized 
value of the likelihood, and 𝑛 is the sample size. The key idea behind these approaches is that 
the more parameters that are used to fit a parametric curve to the observed data, there is a risk 
that there may be overfitting. The resulting overfit prevents an understanding of the true data 
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pattern that is being generated. Thus the AIC and BIC provide scores that penalize parametric 
models that have more parameters. In the context of parametric survival models, Weibull and 
Log-logistic models will have a higher penalty than the exponential model. The interpretation 
of a AIC or BIC score is that, when comparing parametric models, the lower the AIC or BIC 
value the better the model fit. Therefore, for parametric models with more parameters to have 
a better fit, the sums of square error need to be far smaller when extra parameters are used.   
 
Cure survival model 
A cure survival model assumes that certain individuals do not succumb to an event of interest 
[6]. In the context of a cancer diagnosis, these individuals do not succumb to death due to the 
diagnosed cancer, but rather to other factors. These persons are assumed to be ‘statistically 
cured’, and thus are assumed to follow a mortality risk trajectory which follows the 
background population mortality risk. Several types of cure survival models are discussed in 
Lambert et al. However, for the purpose of this thesis, I will focus on the mixture-cure model 
that has been amended and developed by the Roche MORSE Statistics group in the Global 
Pricing and Market Access division.  
 
The general mixture-cure survival and hazard functions are specified as: 
 
𝑆(𝑡) = 𝑆#(𝑡) ∗ [𝜋 + (1 − 𝜋) ∗ 𝑆𝑢(𝑡)] 
 
ℎ(𝑡) = ℎ#(𝑡) + [
(1 − 𝜋) ∗ 𝑓𝑢(𝑡)
𝜋 + (1 − 𝜋) ∗ 𝑆𝑢(𝑡)
] 
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The survival function 𝑆#(𝑡) can be broadly defined as an averaged background population-
based survival outcome of the study sample conditioned on the study sample participant’s 
age, country, or other characteristic that differentiate survival outcomes. The hazard function  
ℎ#(𝑡) is the instantaneous mortality risk at a particular age, given age, country or other 
characteristics. Both 𝑆#(𝑡) and ℎ#(𝑡) are derived from country specific life-tables. The 
parameter 𝜋 is a cure fraction, which is defined as the estimated proportion of the sample 
assumed to not succumb to the event of interest. The final two parameters are the probability 
density function 𝑓𝑢(𝑡) and survival function 𝑆𝑢(𝑡) for the uncured population of the sample. 
These are functions that are fitted according to best fitting parametric function criteria for the 
time-to-event data generating process. The process for determining the best fit has been 
described previously.  
 
Mixture-cure model for stage III colorectal cancer 
The steps I used to calculate the overall cure survival function for the XACT clinical trial 
participants were as follows.  
 
Step 1: Data sources to estimate the cure fraction: - The cure fraction is estimated using a 
combination of background population-based mortality risk and a disease specific registry. In 
this analysis I used the US specific lifetables to estimate background mortality and the SEER 
cancer registry data to represent the disease specific registry. The SEER cancer registry is 
population-based and covers 28% of the population through 18 cancer registries throughout 
the United States [9]. The choice of US data to estimate the cure fraction was based on the 
availability of the SEER cancer registry data. Other population-based cancer registry sources 
could also be used.      
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From the SEER registry I extracted all patients diagnosed with colorectal cancer between 
Jan-1998 to Dec-2001 with stage III disease. This resulted in n=4302 cases. After excluding 
those with a recorded 0 survival time, 4172 cases remained in the dataset.  Variables 
extracted for each case included age and year at diagnosis, survival time, censoring status and 
stage of disease. Background population-based mortality risk were used in the form of US 
specific lifetables that were age and gender specific for the years 1933 to 2014 [10]. 
 
To undertake the estimation process for the cure fraction, a merged dataset was needed that 
included the probability of survival for the disease of interest, and the background mortality 
risk. In this case, each unit record of stage III colorectal cancer was merged with mortality 
risk based on US specific lifetables. US specific lifetables were merged to each individual in 
SEER based on sex, age at death and year at death. In the US lifetables, 𝑛𝑄𝑥 represents the 
probability of death for a particular age in a one year interval. This is a proxy for 
instantaneous background mortality risk. For the merge, the US lifetable variables ‘age’ and 
‘year’ were re-coded to ‘age at death’ and ‘year at death’. In the extracted SEER dataset ‘age 
at death’ was defined as ‘age at diagnosis’ plus ‘survival time’, while ‘year of death’ was 
defined as ‘year of diagnosis’ plus ‘survival time’. The resulting merged table gives each 
participant with stage III colorectal cancer diagnosed in 1998-2001 with an assumed 
population-based background instantaneous risk of death, had they not had the disease of 
interest (in this case colorectal cancer). This estimate is used in the subsequent step to 
estimate the cure fraction for stage III colorectal cancer for patients treated in this period.   
 
Step 2: Estimation of cure-fraction:-  The merged dataset between the SEER colorectal stage III 
patients and US lifetables was used to estimate the cure fraction based on the method of 
maximum likelihood. The log-likelihood function evaluated was: 
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log 𝐿𝑠𝑒𝑒𝑟( 𝜃, 𝜋|𝑡, 𝛿) = ∑ 𝛿𝑖 log[ℎ𝑚𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑒(𝑡𝑖|𝜃
#1, 𝜋# )] +
𝑁
𝑖=1
∑ log[𝜋 + (1 − 𝜋) ∗ 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖|𝜃
#1, 𝜋# )]
𝑁
𝑖=1
 
 
Where 𝑁 is the total number of SEER stage III colorectal cancer patients (𝑖 = 1,2, … ,4172), 
and 𝛿𝑖 is the censoring variable, where a 1= event (death) and 0=censored. In the function, 
log of ℎ𝑚𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑒 , 𝑡𝑖 is time-to-event in years for person 𝑖,  𝜃
#1, 𝜋# are initial parameter 
estimates that act as seeding values to be re-estimated as 𝜃 and 𝜋 using the Newton-Raphson 
root variable approximation. The method of approximating the maximum likelihood for each 
parameter was based on the PROC NLMIXED function (discussed further below).  
 
The hazard function in the log-likelihood equation is calculated as: 
 
ℎ𝑚𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑒(𝑡𝑖|𝜃
#1, 𝜋# ) = 𝑛𝑄𝑥𝑗 +
(1 − 𝜋) ∗ 𝑓𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖| 𝜃
#1)
(𝜋 + 1 − 𝜋) ∗ 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖|𝜃#1)
 
 
The term 𝑛𝑄𝑥𝑗 is a fixed estimate of the 𝑗𝑡ℎ interval instantaneous background mortality for 
person 𝑖  in the SEER database had they not been diagnosed with stage III colorectal cancer. 
The 𝑗𝑡ℎ interval for the instantaneous mortality risk is allocated to each person based on the 
addition of their age and year at diagnosis plus the time to their event (i.e. death). For 
example, the background population instantaneous mortality risk in the US in the year 2004 
for a female at age 68 is 0.01468. This risk would be allocated to any female in the SEER 
databased diagnosed with colorectal cancer female who had an event at aged 68 yrs and their 
death was in the year 2004. The diagnosis would have to been in the year 2002 at age 66 
years.  
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The other components of the hazard function are the probability density function 
𝑓𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖| 𝜃
#1)  and survival function 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖| 𝜃
#1) for the uncured population. These 
functions are estimated for person 𝑖 based on the vector of parameters 𝜃#1. The parameters 
are based on the best fitting parametric function for the time-to-event data for SEER patients 
diagnosed with stage III colorectal cancer.  The basis for determining the best fitting 
parametric curve has been described previously. 
 
To approximate the maximum likelihood I used the PROC NLMIXED procedure. The 
procedure code to evaluate the log-likelihood parameters of interest is presented below: 
Line 1 - proc nlmixed data=colrect_only_d; 
Line 2 - parms / data = parm_surv_estimates; 
Line 3 - f_t = pdf('parametric_dist.', ttdied_yrs, parameter_1,   
parameter_2, parameter_x, … ); 
Line 4 - S_t = 1 - cdf('parametric_dist.', ttdied_yrs, parameter_1, 
parameter_2, parameter_x, … ); 
Line 5 - h_ = qx + (1-pi_)*f_t/(pi_ + (1-pi_)*S_t); 
Line 6 - s_ = pi_ + (1 - pi_)*S_t;   
Line 7 - ret_val =  cens*log(h_) + log(s_);   
Line 8 - model ttdied_yrs ~ general(ret_val); 
Line 9 - ods output parameterestimates = seer_pop_cure_fraction; 
   run; 
 
The first line of the PROC NLMIXED code reflects the dataset used to evaluate the log-
likelihood, in this case I used the merged SEER and US lifetable dataset. The second line is 
the dataset containing the vector of parameters for the best fitting parametric survival 
distribution to the SEER time-to-event dataset. For example, if the log-logistic function was 
the best fitting parametric model, then the intercept, scale parameter are listed. Lines three 
and four are the probability density functions [ 𝑓𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖| 𝜃
#1)]  and the survival functions 
[ 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖| 𝜃
#1)] for person 𝑖, where the calculation for each function is determined by 
specifying the selected parametric survival function equation, the outcome variable (i.e. 
survival time), and the parameters used to calculate the parametric survival function 
(parameter 1, parmameter 2, parameter x, …). Lines five and six calculate the mixed cure 
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hazard function ℎ𝑚𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑒(𝑡𝑖|𝜃
#1, 𝜋# ), and the second component of the log-likelihood 
equation: ∑ log[𝜋 + (1 − 𝜋) ∗ 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖| 𝜃
#1)]𝑁𝑖=1 . In line five qx refers to 𝑛𝑄𝑥𝑗 . Line 
seven is the calculation of the complete log-likelihood for each person 𝑖 in the merged SEER 
dataset. Line eight runs the Newton-Raphson optimization algorithm to estimate the 
maximum likelihood for the parameters in the log-likelihood function. Finally, line nine 
outputs the unknown parameters estimated through the maximum likelihood. These include 
the cure fraction, and re-estimated initial parameters indicated in line 2.  
 
Step 3: Estimation of parametric survival curve parameters in the context of a mixture-cure model: - 
Following an estimate of the cure fraction, I next estimate the mixture-cure model parameters 
for each treatment arm in the Xeloda clinical trial. Similar to the merged SEER and US 
dataset, I merged each observation in the Xeloda clinical trial dataset with country specific 
lifetables according to sex, country, age at death and year of death. 
 
In the first instance, initial parametric survival distribution parameters are estimated for each 
treatment arm based on the assumed context that there is no cure. These initial starting 
parameters are substituted in the log-likelihood equation of each treatment arm, along with 
the derived fixed estimate of the cure fraction: 
 
log 𝐿5𝐹𝑈+𝐿𝑒𝑣( 𝜃
∗|𝑡, 𝛿, 𝜋) =∑ 𝛿𝑖 log[ℎ𝑚𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑒(𝑡𝑖|𝜃
#2, 𝜋 )] +
𝑁
𝑖=1
∑ log[𝜋 + (1 − 𝜋) ∗ 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖|𝜃
#2)]
𝑁
𝑖=1
 
 
log 𝐿𝐶𝑎𝑝( 𝜃
∗|𝑡, 𝛿, 𝜋) = ∑ 𝛿𝑖 log[ℎ𝑚𝑖𝑥𝑒𝑑 𝑐𝑢𝑟𝑒(𝑡𝑖|𝜃
#2, 𝜋)] +
𝑁
𝑖=1
∑ log[𝜋 + (1 − 𝜋) ∗ 𝑆𝑢𝑛𝑐𝑢𝑟𝑒𝑑(𝑡𝑖|𝜃
#2)]
𝑁
𝑖=1
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Where 𝜃∗are the re-estimated vector of parameters for the parametric survival distribution 
that has an assumed cure fraction. The vector of parameters 𝜃#2 are initial seeding values 
based on the best fitting parametric survival distribution in the assumed context that there is 
no cure. Similar to the The log-likelihood function for the SEER dataset, the log-likelihood 
for each treatment arm is evaluated using method of maximum likelihood using the PROC 
NLMIXED procedure. 
 
Step 4: Calculation of mixture-cure survival curves: - Once parameters for the mixture survival 
model are calculated, the next step is substitution of estimated parameters into the survival 
functions: 
 
𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗ [+(1 − 𝜋) ∗ 𝑆𝑢(𝑡𝑖|𝜃
∗)] 
 
𝑆𝐶𝑎𝑝(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗ [𝜋 + (1 − 𝜋) ∗ 𝑆𝑢(𝑡𝑖|𝜃
∗)] 
 
Where 𝑆#(𝑡)𝑗 is an ‘averaged’ background population survival probability for a particular 
follow-up year (jth group, where 𝑗 = 𝑦𝑒𝑎𝑟 1, 𝑦𝑒𝑎𝑟 2…𝑦𝑒𝑎𝑟 30).   𝑆#(𝑡)𝑗 =
1
𝑁
∑
𝑆𝐵(𝑎𝑖+𝑡)
𝑆𝐵(𝑎𝑖)
𝑁
𝑖=1  . 
Where 
𝑆𝐵(𝑎𝑖+𝑡)
𝑆𝐵(𝑎𝑖)
 is a conditional probability defined as a clinical trial participant’s ‘theoretical’ 
non-cancer survival probability for their gender country of treatment  (𝑆𝐵) at age (𝑎𝑖) plus 
(𝑡), where 𝑎𝑖 is the age at the point of randomization and 𝑡 is the time to the event (death), 
divided by trial participant’s ‘theoretical’ non-cancer survival probability (𝑆𝐵) at age (𝑎𝑖).  
The summation is over all the individuals in the clinical trial. Figure 1 displays the 
background survival probability of individual trial participants had they not had the disease 
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(black survival probability curves lines) and the average for the sample (red survival 
probability)  
 
The remaining parameters for the cure model’s overall survival function are the cure fraction 
(𝜋) and the re-estimated vector of parameters for the best fitting parametric survival 
population for the non-cure group 𝑆𝑢(𝑡𝑖|𝜃
∗). In this case 𝜃∗ is the re-estimated vector of 
parameters based on the notion that a cure proportion has been accounted for in the 
maximization of the log-likelihood.  
 
Figure 1 : XACT trial participant’s background survival probablity of stage III 
colorectal cancer patients (black) and their average background survival probability for 
all trial participants (red) 
 
 
Step 5: Fitting mixture-cure survival curves: - The final step in estimating survival with the use 
of the mixture-cure model was re-calibrating the parameters to fit the observed data. As 
outlined previously, the derivation of the cure fraction for the clinical trial population with 
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stage III colorectal was derived from an external source population. In this case, the cure 
fraction was derived from the US SEER population of stage III colorectal cancer who were 
diagnosed in the same time period as the participants in the XACT clinical trial. One of the 
concerns with this approach is that the external population might not reflect the broad 
characteristics of the trial population. For example, the population used to derive the cure 
fraction may be older, have more advanced disease or some other characteristic of disease 
that leads to a greater accerlerated failure time. This can be observed by comparing the non-
parameteric curves for the clinical trial population (based on the first datacut) and the SEER 
population (Figures 1 and 16). The survival curves show that the clinical trial population has 
a higher survival probability at the 4-5 year follow-up period (60-80%) compared with the 
SEER stage III population (50-60%). Therefore, to adjust for the lower survival probability 
from which the cure fraction was derived, the cure fraction may need to be re-calibrated. In 
this case the cure fraction needs to be re-calibrated upwards to a point where the mixture-cure 
survival estimate follows the general trend of the clinical trial population. The approach used 
to fit the re-calibrated curves was based a visual comparison of multiple cure fraction 
estimates to the observed non-parametric curve for each treatment arm. 
 
Extrapolation beyond observed survival: 
Each treatment arm had survival extrapolated beyond observed survival time. This was based 
on using the selected best fit parametric survival curve and the re-calibrated mixture-cure 
survival model (as defined above), and applying the model’s parameters to time (years) 
beyond what was observed in the clinical trial. For the 5FU+Leucovorin arm extrapolation 
was from the last participant observation time of 8.63 years to 50 years, while for the 
Capecitabine it was from 8.54 years up to 50 years aswell.  
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Results   
 
XACT trial 
In the XACT trial there were 1987 participants across 25 countries diagnosed with stage III 
colorectal cancer. 983 were randomized to 5FU+Leucovorin, while 1004 were randomized to 
Capecitabine. The median ages at diagnosis of participants in each arm were 63 and 62 years, 
respectively. Both treatment arms have left skewed age distributions, with most patients 
(85%) in the 55 to 85 year age group (Figure 2). The remaining 15% of participants were 
aged between 20 to 55 years.  Most participants were diagnosed with stage IIIB disease (62% 
and 60%), while in both treatment arms there were more males (54%) than females (46%).  
In the first datacut (i66001d) 23% of participants in the 5FU+Leucovorin arm had an event 
(died), while in the Capeciabine arm it was 20%. In the final datacut (i66001h) the proportion 
of patients who had an event increased to 36% and 32%. The median follow-up time for the 
first datacut was approximately 3 years (maximum follow-up 5years), while in the final 
datacut it was around 5 years (maximum follow-up 8 years).  
Non-parametric survival outcomes: In the first datacut median survival was not reached in either 
treatment arm (Figure 3). Among those randomized to 5FU+Leucovorin 25% of participants 
had an event at 3.45 years (95% CI 3.06 – 4.11 years). For those randomized to  Capecitabine 
arm it was 3.98 yrs (95% CI 3.68 -  . ).  However this difference was not statistically 
significant (Log-rank 3.23, p-value 0.07; Wilcoxon test value 3.08, p-value 0.079).  
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Table 1: Baseline characteristics of clinical trial population by treatment arm 
 5FU + Leucovorin Capecitabine 
 n (%) n (%) 
Number at randomization (ITI) 983 1004 
Number of events   
First data cut (i6600d)   
Event (death) 227 (23) 200 (20) 
Censored 756 (77) 804 (80) 
Final data cut (i6600h)   
Event (death) 351 (36) 319(32) 
Censored 632 (64) 685 (68) 
Median follow-up   
First data cut (i6600d) 2.95 yrs  (min:0.03 – max: 5.42) 3.01 yrs (min: 0.03 – max: 5.23) 
Final data cut (i6600h) 5.12 yrs  (min: 0.03 – max: 8.63) 5.27 yrs (min: 0.03 – max: 8.54) 
Sex   
Male 532 (54) 542 (54) 
Female 451 (46) 461 (46) 
Median age (range) 63 yrs (Q1: 55, Q3:69) 62 yrs (Q1: 54, Q3:68) 
Tumor stage   
Stage IIIA 82 (9) 92 (9) 
Stage IIIB 612 (62) 603 (60) 
Stage IIIC 288 (29) 305 (31) 
 
Figure 4 presents the estimated observed hazard rate for the first datacut. The the rate at 
which events occurr in each treatment arm appears to increase until approximately 2-2.5 
years. After this time point the rate of events appears to remain constant in the Capecitabine 
arm, whereas the rate of events in the 5FU+Leucovorin arm continues to increase at a 
decreasing rate. Figures 5 and 6 provide additional insight into the rate of events. Figure 5 
suggests a steady similar rate from beginning in each treatment arm until approximately 2 
years. After this time point participants in the 5FU+Leucovorin arm display an increasing 
rate of events relative to the Capecitabine arm. Figure 6 shows a similar pattern with a slower 
rate of events initially, then an increase in the rate swith a slight divergence at 2.5 yrs 
(ln(0.92) on the x-axid of figure 6). 
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Figure 2: Histogram of age at randomization overlay by treatment group 
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Figure 3: Kaplan-Meier overall survival curves by 
treatment arm (datacut i6600d) 
Figure 4: Empirical estimate of the hazard function 
for time to death events (datacut i6600d) 
  
Figure 5: Cumulative hazard function by treatment 
arm (datacut i6600d) 
Figure 6: Log-cumulative hazard function by 
treatment arm (datacut i6600d) 
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Standard parametric survival outcomes:  The parametric functions used to plot survival 
according to the initial datacut are displayed in Table 2. The resulting survival curves are 
displayed in Figures 7-16. Figures 7-11 display the parametric hazard function that should be 
consistent in shape with the estimated hazard function displayed in Figure 4.  When 
compared to figure 4 the weibull, log-logistic, and gamma appear to show similar pattern of 
increasing rate of the events, then a decrease in the rate of increase. The same set of 
parametric functions also appear to show reasonable fit when parametric survival is compared 
with the Kaplan-Meier curve (Figures 12-16). The visual fit is evident before approximately 2 
years when there is heavy censoring. When the criteria of fit include AIC scores (Table 3), 
the log-logistic function has the lowest value (AIC: 2607.58). 
 
 
Table 2: Parametric survival equations for each treatment arm based on first data cut 
Parametric 
survival 
model 
Parameterized functions 
5FU+Leucovorin Capecitabine 
Exponential exp [− exp(−[0.0783]) ∗ 𝑡𝑖] exp [− exp(−[0.0661]) ∗ 𝑡𝑖] 
Weibull 
exp [−exp (−
0.0469
1.4357
)∗ 𝑡𝑖
1
1.4357] 
 
exp [− exp (−
0.0393
1.4357
)∗ 𝑡𝑖
1
1.4357] 
Log-normal 
1 − 𝜑 ∗ (
[log(𝑡𝑖) − (2.1955)]
1.3373
) 
 
1 − 𝜑 ∗ (
[log(𝑡𝑖) − (2.3236)]
1.3373
) 
 
Log-logistic 
1
(1 + exp (
−[0.0474]
1.5480 ) ∗ 𝑡𝑖
1
1.5480)
 
1
(1 + exp (
−[0.0389]
1.5480 ) ∗ 𝑡𝑖
1
1.5480)
 
Gamma (
1
0.94642
) ∗ (exp(−(0.2196))
0.9464
1.6733) (
1
0.94642
) ∗ (exp(−(0.1951))
0.9464
1.6733) 
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Figure 7: XACT Exponential parametric hazard 
function estimate (datacut i6600d) 
Figure 8: XACT Weibull parametric hazard function 
estimate (datacut i6600d) 
  
Figure 9: XACT Llogistic parametric hazard function 
estimate (datacut i6600d) 
Figure 10: XACT Lnormal parametric hazard function 
estimate (datacut i6600d) 
  
Figure 11: XACT Gamma parametric hazard function estimate (datacut i6600d) 
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Figure 12: Exponential survival function by treatment arm 
(datacut i6600d) 
Figure 13: Weibull survival function by treatment arm 
(datacut i6600d) 
  
Figure 14: Log-logistic survival function by treatment arm 
(datacut i6600d) 
Figure 15: Log-normal survival function by treatment arm 
(datacut i6600d) 
  
Figure 16: Gamma survival function by treatment arm 
(datacut i6600d) 
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Table 3: AIC scores for modelled parametric survival curves for  XACT trial participants  
Parametric function AIC score 
Exponential 2666.00 
Weibull 2610.71 
Log-logistic 2607.58 
Log-normal 2630.97 
Gamma 2611.57 
 
Mixture-cure model 
The SEER dataset used to estimate the cure-fraction had 4,302 registered stage III colorectal 
cancer cases diagnosed between 1998-2001. Of these 131 (3%) had a survival time recorded 
as ‘0’. After excluding these, there remained 4,171 cases. Between January 1998 to 
December 2013, 72% of cases had a recorded event. The median survival in this population 
was 5 years (95% CI 4.75 – 5.25 years), with 25% of events occurring at 2 years (95% CI 
1.83 – 2.08 years) (Figure 17). The parametric functions used to estimate survival in this 
population are displayed in figures 18 – 22. Of these functions the gamma, log-normal and 
log-logistic survival curves appear to remain within the bounds of the 95% confidence limits 
of the Kaplan-Meier curve. Similarly, the parametric hazards for the log-normal and the log-
logistic functions (Figures 27 and 28) appear to show a similar shape as the estimate observed 
hazard (Figures 23).  Adding the additional criteria of AIC score (Table 4), the log-logistic 
parameter function has the lowest value out of all the models (AIC 13596.31).  
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Figure 17: Kaplan-Meier curve for SEER stage III 
colorectal cancer cases diagnosed between 1998-2001 
Figure 18: Kaplan-Meier vs Weibull parametric 
survival model for SEER stage III colorectal 
cancer 
  
Figure 19: Kaplan-Meier vs Exponential parametric 
survival model for SEER stage III colorectal cancer 
Figure 20: Kaplan-Meier vs Gamma parametric 
survival model for SEER stage III colorectal 
cancer 
 
 
Figure 21: Kaplan-Meier vs Log-logistic parametric 
survival model for SEER stage III colorectal cancer 
Figure 22: Kaplan-Meier vs Log-normal 
parametric survival model for SEER stage III 
colorectal cancer 
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Figure 23: Estimated empirical hazard rates for 
SEER patients diagnosed with stage III colorectal 
cancer (CC) between 1998-2001 
Figure 24: SEER Weibull parametric hazard 
function for patients diagnosed with stage III CC 
  
Figure 25: SEER Exponential parametric hazard 
function for patients diagnosed with stage III CC 
Figure 26:  SEER Gamma parametric hazard 
function for patients diagnosed with stage III CC 
 
 
Figure 27:  SEER Log-logistic parametric hazard 
function for patients diagnosed with stage III CC 
Figure 28:  SEER Log-normal parametric hazard 
function for patients diagnosed with stage III CC 
  
40 
 
 
Table 4:  AIC scores for modelled parametric survival curves for SEER registered 
colorectal cancer stage III cases diagnosed between 1998-2001 
Parametric function AIC score 
Exponential 13961.85 
Weibull 13750.09 
Log-logistic 13596.31 
Log-normal 13612.20 
Gamma 13603.80 
 
Parameter estimates for the mixture-cure models: The set of mixture-cure equations used to plot 
overall survival for each treatment arm are displayed in Table 5. For the background 
mortality term 𝑆#(𝑡)𝑗 in each equation, survival for each clinical trial participant in the 
absence of colorectal cancer stage III is displayed in Figure 1 (blackline). The first mixture-
cure model was used to estimate the cure fraction 𝜋 based on the SEER population (Table 6). 
Based on the fit of the SEER population to the parametric survival and hazards curves, as 
well as the AIC criteria, the vector of parameters based on the log-logistic model was used to 
seed the SEER log-likelihood mixture-cure model [log−𝐿𝑠𝑒𝑒𝑟( 𝜃, 𝜋|𝑡, 𝛿)]. Maximum 
likelihood estimate for the cure fraction was 0.58 (Table 6).  
The second set of mixture-cure models was used to re-estimate the log-logistic vector of 
parameters, 𝜃∗ , in each treatment arm based on an initial cure fraction, 𝜋 ,estimate of 0.58 
(Table 6). The maximized log-likelihood mixture cure model equation for 5FU+Leucovorin 
was log [𝐿5𝐹𝑈+𝐿𝑒𝑣( 𝜃
∗|𝑡, 𝛿, 𝜋)]. The intial set of parameters, 𝛿, were 1.9461 and 0.6286. For 
the Capecitabine arm the log-likelihood maximized equation was log [𝐿𝐶𝑎𝑝( 𝜃
∗|𝑡, 𝛿, 𝜋)] with 
an initial set of parameters, 𝛿, of 2.0330 and 0.6468. The re-estimated log-logisitic 
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parameters, 𝜃∗, for a 0.58 cure fraction estimate was 3.1642 and 0.8889 for the 
5FU+leucovorin treatment arm, and 3.462 and 0.9614 for the Capecitabine arm (Table 6). As 
the cure fraction was re-calibrated upward for each treatment arm to fit the survival curve 
based on the initial datacut, the parameter values decreased to 2.5422 and 0.6755 for the 
5FU+Leucovorin arm, under the assumption of a cure fraction of 0.69. For the Capecitabine 
arm the re-estimated values were 2.3769 and 0.6128 for an assumed cure fraction of 0.78.  
 Table 5: Mixture-cure model parametric overall survival equations 
CF 5FU+Leucovorin 
0.58 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.58 + (1 − 0.58) ∗
[
 
 
 
 
1
(1 + exp (
−3.1642
0.8889 ) ∗ 𝑡𝑖
1
0.8889)
]
 
 
 
 
 
}
 
 
 
 
 
0.62 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.62 + (1 − 0.62) ∗
[
 
 
 
 
1
(1 + exp (
−2.9058
0.8048 ) ∗ 𝑡𝑖
1
0.8048)
]
 
 
 
 
 
}
 
 
 
 
 
0.65 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.65 + (1 − 0.65) ∗
[
 
 
 
 
1
(1 + exp (
−2.7309
0.7440 ) ∗ 𝑡𝑖
1
0.7440)
]
 
 
 
 
 
}
 
 
 
 
 
0.69 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.69 + (1 − 0.69) ∗
[
 
 
 
 
1
(1 + exp (
−2.5422
0.6755 ) ∗ 𝑡𝑖
1
0.6755)
]
 
 
 
 
 
}
 
 
 
 
 
 Capecitabine 
0.58 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.58 + (1 − 0.58) ∗
[
 
 
 
 
1
(1 + exp (
−3.4625
0.9614 ) ∗ 𝑡𝑖
1
0.9614)
]
 
 
 
 
 
}
 
 
 
 
 
0.69 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.69 + (1 − 0.69) ∗
[
 
 
 
 
1
(1 + exp (
−2.7533
0.8048 ) ∗ 𝑡𝑖
1
0.7449)
]
 
 
 
 
 
}
 
 
 
 
 
0.75 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.75 + (1 − 0.75) ∗
[
 
 
 
 
1
(1 + exp (
−2.6022
0.7440 ) ∗ 𝑡𝑖
1
0.6933)
]
 
 
 
 
 
}
 
 
 
 
 
0.78 𝑆5𝐹𝑈+𝐿𝑒𝑣(𝑡𝑖) = 𝑆
#(𝑡)𝑗 ∗
{
 
 
 
 
0.78 + (1 − 0.78) ∗
[
 
 
 
 
1
(1 + exp (
−2.3769
0.6755 ) ∗ 𝑡𝑖
1
0.6128)
]
 
 
 
 
 
}
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Table 6: Mixture-cure model maximized log-likelihood parameter values 
Population 
Parametric 
Model Seed parameters 
Maximised Log-
Likelihood parameter 
values 
  𝜆 𝑝 𝜋 𝝀 𝒑 𝝅 
SEER Stage III Log-logistic 1.6762 0.9442 0.25 2.7470 1.0012 0.58 
5FU+Leucovorin 
Log-logistic 
(scenario 1) 
1.9461 0.6286 0.58∗ 3.1642 0.8889 NA 
Log-logistic 
(scenario 2) 
1.9461 0.6286 0.62∗ 2.9058 0.8048 NA 
Log-logistic 
(scenario 3) 
1.9461 0.6286 0.65∗ 2.7309 0.7440 NA 
Log-logistic 
(scenario 4) 
1.9461 0.6286 0.69∗ 2.5422 0.6755 NA 
Capecitabine 
Log-logistic 
(scenario 1) 
2.0330 0.6468 0.58∗ 3.4625 0.9614 NA 
Log-logistic 
(scenario 2) 
2.0330 0.6468 0.69∗ 2.7533 0.7449 NA 
Log-logistic 
(scenario 3) 
2.0330 0.6468 0.75∗ 2.6022 0.6933 NA 
Log-logistic 
(scenario 4) 
2.0330 0.6468 0.78∗ 2.3769 0.6128 NA 
* The cure fraction is a fixed estimate in the maximization of the log-likelihood; 𝜋 cure-fraction; 𝜆 is the intercept 
term (𝛽0) for the 5FU+Leucovorin arm, or the intercept plus coefficient value for the Capecitabine arm (𝛽0 + 𝛽1𝑥); 
𝑝 is the scale parameter. 
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Assessing the best-fit parametric model 
Figures 29-32 display the Kaplan-Meier curves for the initial datacut for each treatment arm, 
as well as the fitted parametric and mixture-cure survival curves. For the fitted curves (classic 
and mixture-cure) survival were extrapolated to 10 years. Among the standard set of 
parametric curves, the log-logistic model displays the best fit to the initial data cut of 
observed survival (Figures 29 and 30) when using the visual comparison between observed 
versus modelled functions (survival and hazard) and AIC criteria. The best fitting mixture-
cure model for the 5FU+Leucovorin arm was based on a cure-fraction estimate of 0.69 
(Figure 31), while for the Capecitabine arm the best fit model was based on a cure-fraction 
estimate of 0.78 (Figure 32). Given the intent of the mixture-cure model is to account for the 
potential cured proportion, which is consistent for patients diagnosed with colorectal cancer 
treated with curative intent, the mixture-cure models were selected as the best predictor of 
survival up to 10 years. Among the modelled mixture-cure models, the cure-fraction of 0.69 
is my prediction of the best fit for the 5FU+Leucovorin arm, while a cure-fraction of 0.78 is 
my prediction of the best fit for the Capecitabine arm. 
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Figure 29: 5FU+Leucovorin treatment arm comparison of non-parametric and extrapolated parametric survival curves 
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Figure 30: Capecitabine treatment arm comparison of non-parametric and extrapolated parametric survival curves 
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Figure 31: 5FU+Leucovorin treatment arm comparison of non-parametric and extrapolated mixture cure parametric survival curves 
by cure fraction 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 1 2 3 4 5 6 7 8 9 10
Su
rv
iv
al
 p
ro
b
ab
ili
ty
 
Time (Years) 
5FU+Leucovorin KM CF=0.58 CF=0.62 CF=0.65 CF=0.69
47 
 
Figure 32: Capecitabine treatment arm comparison of non-parametric and extrapolated mixture cure parametric survival curves 
by cure fraction 
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Model validation 
Non-parametric survival outcomes of final XACT trial data-cut: Figures 33-35 display the non-
parametric survival outcomes for each treatment arm based on the last datacut (i66001h). 
Median survival was not reached during the final datacut (Figure 33). At the final datacut,  
25% of the sample had an event in the 5FU+Leucovorin arm at 3.70 years (95% CI 3.16 – 
4.34 years), while for the Capecitabine arm the same proportion of events occurred at 4.21 
yrs (95% CI 3.71 – 4.80 ).  While there appears to be a difference between the treatment arms 
in the time point at which 25% of the sample experienced an event, this difference was not 
statistically significant (Log-rank 3.54, p-value 0.0598; Wilcoxon test value 2.76, p-value 
0.0961).  
The difference in the hazard rate at which events occurred in each treatment arm appears to 
show an increasing rate of death until approximately 2.5-3 years where the peak is reached 
(Figure 34). After this point, the rate of events declines at a similar rate in each treatment 
arm. However in both arms the rates tend to pick-up in the tail of the curves, yet these may be 
unreliable given the small number of events at this point. Figure 35 also provides insight into 
the rate at which the hazard is occurring. The log of the cumulative hazard relative to the log 
of time shows a slower rate of events initially, then an increase in the rate subsequently with a 
slight divergence at 2.5 yrs (ln(0.92) on the x-axis of figure 35) between the two treatment 
arms. 
Best-fit parametric survival curves vs observed survival: Figures 36 and 37 display the observed 
survival for the final datacut for each treatment arm and the corresponding best fit parametric 
model based on the classic parametric and the mixture-cure models. The classic parametric 
models are predictions of the final datacut based on the observed events in the first datacut. 
The mixture-cure model with a cure-fraction of 0.69 appears to be a better fit compared with 
the observed survival in the  5FU+Leucovorin treatment arm (Figure 33). In the initial stages 
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of observation, the log-logistic curve appears to follow the observed survival at 
approximately 3.5 years. However, as more patients are observed, the log-logistic prediction 
becomes too aggressive relative to the observed survival. In contrast the mixture-cure fraction 
while initially over-estimating the failure rate, appears to converge towards a similar 
trajectory as the observed survival.  
For the Capecitabine arm (Figure 34), the mixture-cure model with a cure fraction of 0.78 
appears to be the best fit compared with the observed overall survival. Similar to the initial 
trajectory for the 5FU+Leucovorin arm, the log-logistic model appears to display a better fit 
upto observed survival at approximately 4 years. However, the trajectory becomes too 
aggressive and subsequently overestimates the failure proportion as time progresses. In 
contrast, the mixture-cure model follows the trajectory of the observed survival proportion, 
justifying its choice as a better parametric fit.   
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Figure 33: Kaplan-Meier overall survival curves by 
treatment arm (datacut i6600d) 
Figure 34: Empirical estimate of the hazard 
function for time to death events (datacut i6600d) 
  
Figure 35: Log-cumulative hazard function by treatment arm (datacut i6600d) 
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Figure 36: 5FU+Leucovorin treatment arm final data cut observed vs predicted overall survival 
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Figure 37: Capecitabine treatment arm final data cut observed vs predicted overall survival 
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Extrapolation beyond observed survival: Beyond the period of observed survival time, 
extrapolated survival for the log-logisitic model follows a different survival trajectory from 
that of the extrapolated mixture-cure model.  For the 5FU+Leucovorin arm (purple line – 
Figure 38) the observed survival for the initial data-cut is followed closely using the predicted 
log-logisitic survival function (dashed orange line). This is the same for the  Capecitabine 
arm (green line – Figure 39). The predicted log-logistic survival trajectory diverges from 
observed survival for the final datacut (5FU+Leucovorin - red line, Figure 38; Capecitabine – 
black line, Figure 39 ), illustrating a more aggressive probability of death. In contrast, the re-
calibrated mixture-cure models initially underestimate the observed survival for both 
treatment arms, but then begins to follow the trajectory for the final datacut. As the trajectory 
of the log-logisitic model continues the survival probability tail at older years  (between 30 – 
50 years after age at randomization) displays overly optimistic outcome, such that the 
probability of death occurs at a slower rate at older ages. In contrast the mixture-cure model 
displays a probability survival that is less aggressive due to the cured proportion who have a 
trajectory that is consistent with their age that is similar to the background population. 
Towards the tail the mixture-cure model is less optimistic with a small proportion of patients 
alive at 50 years after age at randomization. This is likely to reflect the small proportion of 
patients who a less than 55 years of age. 
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Figure 38: 5FU+Leucovorin treatment predicted modelled long term survival vs observed survival 
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Figure 39: Capecitabine 5FU+Leucovorin treatment predicted modelled long term survival vs observed survival 
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Discussion 
My objectives in this thesis were to firstly fit a set of parametric and mixture-cure models to 
overall survival in patients diagnosed with stage III colorectal cancer treated with curative 
intent, based on an initial data-cut of the XACT clinical trial. Secondly, I assessed which set 
of parametric models (classic and mixture-cure) best fit the observed overall survival based 
on the same initial data-cut. Finally, I evaluated the selected best fit parametric models 
predicted observed overall survival based on the trials final datacut, and used these to derive 
long-term survival estimates. My main findings in this analysis were that classic parametric 
models are unlikely to accurately reflect observed overall survival in the XACT clinical 
patients diagnosed with stage III colorectal cancer treated in the adjuvant setting. The best fit 
parametric function (log-logistic) appeared to fit well to the overall survival based on the 
initial XACT trial datacut. However, when compared with the trial’s final datacut, the 
predicted log-logistic overall survival trajectory overestimated stage III colorectal cancer 
failure probability. In contrast, when the mixture cure model was calibrated to the initial 
XACT trial datacut, its predicted overall survival trajectory appeared to broadly follow the 
pattern of observed overall survival calculated using the final datacut.  
 
A key component of this analysis was the use of the mixture-cure model and the derivation of 
the cure fraction estimate. For this analysis I used the SEER population of patients diagnosed 
with stage III colorectal cancer between 1998-2001. The initial estimated cure fraction, when 
used in the mixture-cure model to derive predicted survival, dramatically underestimated the 
observed survival of the clinical trial population based on the initial datacut. This resulted in 
the need to recalibrate the cure-fraction so the predicted survival approximated the observed 
survival (of the initial datacut). The underestimate of the cure-fraction based on the SEER 
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population presents one of the issues of using an external population which may not be 
similar to the clinical trial population in which a cost-effectiveness model is being developed.  
The difference was evident when non-parametric survival curves for the clinical trial 
population had a higher survival probability at the 4-5 year follow-up period (60-80%) 
compared with the SEER stage III population (50-60%). To ensure that an external 
population used to derive the cure-fraction is broadly similar with the clinical trial population 
to be modelled, an exploratory analysis using Cox proportional hazards modeling could be 
used to assess which variable may explain the difference between the two populations.    
 
Extrapolation of survival was the final part of the analysis for my thesis. Predicted survival 
was modelled for 50 years at age of randomization for each treatment arm using the best-fit 
parametric model and the re-calibrated mixture cure model. In this thesis I argue that the 
mixture-cure model is the best-fit model when the final datacut for observed survival is used. 
In contrast, the parametric model selected as the best fit, while initially the better fit based on 
the first datacut, over-estimates the probability of failure. Consequently, when the mixture-
cure and the log-logistic survival models are projected beyond the observed survival, the two 
sets of trajectories provide striking different survival patterns. The log-logistic model 
overestimates the probability of failure in the initial period after randomization between 0-20 
years, however, towards the 30- 50 year period predicted survival is overly optimisitic. The 
long tails of the log-logisitic and log-normal models is one of their limitations in 
extrapolating predicted survival. In contrast the mixture-cure model takes into account a 
proportion of the population who are cured. The survival trajectory therefore captures 
outcomes that reflect background mortality for certain proportion of the clinical trial 
population. This results in a predicted survival trajectory that is more optimisitic in the initial 
period after randomization, which then becomes more aggressive towards the tail. However, 
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it should be borne in mind that the survival trajectory for a mixture-cure model will be 
dependent on the age characteristics of the trial population. A different age population 
structure will yield different long-term mixture-cure predicted survival. 
 
The final area of discussion for the thesis I would like to address is around ‘uncertainty’. 
Sampling variability was assessed in this thesis through simple approaches such as the 95% 
confidence interval for the observed Kaplan-Meier curves. However, for each of the 
parametric and mixture-cure models, point estimate of the parameters were used to estimate 
predicted survival. One of the limitations of this thesis is that the uncertainty around these 
point estimates (alone and combined) were not explored in great detail. The method of 
maximum likelihood using PROC NLMIXED provides standard errors for each of the 
parameters. To have addressed the uncertainty further I would have like to have used monte-
carlo simulation to explore the combined uncertainty with each set of parameter estimates in 
the parametric and mixture-cure models. Using the range of point estimates from the monte 
carlo simulation, I would apply each of these to the time points for each predicted event. 
While I believe the direction of the predicted survival trajectory would not have changed, the 
range of the estimates of the projected survival trajectory would be worth assess for the 
purposes of estimating the variability in the ICER.  
 
In addition to addressing statistical uncertainty, I would like to have compared the predicted 
survival estimates with one or more population-based and/or clinical cancer registries. The 
population-based registries could provide insight as to how well those diagnosed with stage 
III colorectal cancer in the general population follow the predicted long term survival 
trajectory based on the XACT clinical trial patient characteristics. If there were differences 
(and there are likely to be differences based on the SEER and XACT trial Kaplan-Meier 
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curves), multivariate analysis using Cox regression could be used to assess which clinical 
characteristics (covariates) may/may not explain the difference between the predicted and 
actual survival trajectories.  
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Appendix  
 
/*******************************************************/ 
/*MACRO to generate standard parametric survival curves*/ 
/*******************************************************/ 
 
/*Macro for for the 1st datacut starts here i66001d.pbe*/ 
 
/*----------------------------------------------------------------------------** 
** 
**   DESCRIPTION:   Assessment of model fit to 1st data cut - Xeloda  
** 
**        INPUTS:   work.effic4 
**                   
**       OUTPUTS:   Range of STEM outputs 
** 
**         NOTES:   This work is completed for a Masters Biostats thesis 
** 
**----------------------------------------------------------------------------** 
** 
** LOCATION     : $Source: / $ 
** 
** VERSION      : $Id:  $ 
** 
** AUDIT        : 
**                 
**----------------------------------------------------------------------------**/ 
 
/**----------------------------------------------------------------------------** 
 
**  Initialise macros/set options and libnames 
 
**----------------------------------------------------------------------------**/ 
 
/*sets general option and includes all MORSE macros*/ 
%include "$PROD/morse/sas/morse_init.sas"; 
 
/*%let pop_in=ITT; *Population used in the analysis;*/ 
/*%let treat_us=rnd; *Treatment used in the analysis;*/ 
/*%let cut_off=11 Feb 2014;*/ 
 
proc datasets lib = work mt = data kill nowarn nolist; 
run; 
quit; 
 
/**----------------------------------------------------------------------------**/ 
 
  /**Arrange data to be read in stem macro**/ 
 
/**----------------------------------------------------------------------------**/ 
 
/*** This is the efficacy data ***/; 
 
data event_b; 
     set ana.effic; 
     label rndshortn = "Randomized Treatment Group"  
          ttdfs_m = "Time to disease relapse (months)" 
          ttdied_m = "Time to death (months)"; 
     ttdied_m = ttdied / (356.25/12); 
     ttdfs_m = ttdfs /(365.25/12); 
     ttdfs_yrs=ttdfs_m/12; 
     ttdied_yrs = ttdied/356.25; 
     pop_itt=1; 
     if rnd = "CAPECITABINE" then rndshortn = 2; 
     else if rnd = "5-FU + LEUCOVORIN" then rndshortn = 1; 
run; 
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proc sort data = work.event_b; 
     by proto crtn pt; 
run; 
  
/** 
variable name definitions ana.effic: -  
 proto = protocol 
 crtn = clinical research task number 
 pt = patient number 
**/ 
 
 
/*** This is the demographic data ***/; 
 
data demo_b; 
  set ana.demoext; 
  keep proto crtn pt age sex trt1 trt1dt rnd s_cntry rndshortn pop_itt; 
  pop_itt=1; 
  if rnd = "CAPECITABINE" then rndshortn = 2; 
  else if rnd = "5-FU + LEUCOVORIN" then rndshortn = 1; 
run; 
   
proc sort data = work.demo_b; 
     by proto crtn pt; 
run; 
   
/** 
variable name definitions for ana.demoext: -  
 proto = protocol 
 crtn = clinical research task number 
 pt = patient number 
 trt1 = first trial medication 
 trt1dt = first trial medicatoin begin SAS datetime 
 rnd = randomisation treatment 
**/ 
run; 
 
*** create a new document ***; 
options noquotelenmax; 
 
%util_document_new(document_name = stem); run; 
 
%stem_macro(dsin          = event_b 
           ,demo          = demo_b 
           ,dsin_where    = pop_itt=1 
           ,demo_where    = pop_itt=1 
 
           ,usubjid       = pt 
           ,rxn           = rndshortn 
           ,rxc           = rnd 
 
           ,stratvar      =  
 
           ,timevar       = ttdied_yrs 
           ,censvar       = censdied 
           ,censval       = 0 
 
           ,document_name = stem 
           ,outdoc_prefix = os 
 
           ,title1        = "Study: XACT, Population: Adjuvant treatment stage III colon cancer" 
           ,title2        = "Duration of overall Survival" 
 
           ,footnote1     = "Cap = CAPECITABINE" 
           ,footnote2     = "5fu_leu = 5-FU + LEUCOVORIN" 
); 
run; 
 
 
/*** output the selected outputs ***/; 
%util_document_play(document_name = stem 
                   ,outpath       = $HOME/cd10743d.pbe/i66001d.pbe/reports 
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                   ,outfiles      =  
 
 
  ex1_all_os.pdf 
  [ 
    os_km_pl 
    os_lr_inf 
    os_lrkm_pl_est 
    os_lr_est 
    os_lr_est_expo 
    os_lr_est_weib 
    os_lr_est_llog 
    os_lr_est_gamm 
    os_lr_est_lnor 
    os_km_plt_h 
    os_km_plt_s 
    os_km_plt_ls 
    os_km_plt_lls 
    os_lrkm_plt_expo 
    os_lrkm_plt_weib 
    os_lrkm_plt_llog 
    os_lrkm_plt_lnor 
    os_lrkm_plt_gamm 
    os_lr_plt_expo 
    os_lr_plt_weib 
    os_lr_plt_llog 
    os_lr_plt_lnor 
    os_lr_plt_gamm 
    os_lrhaz_plt_expo 
    os_lrhaz_plt_weib 
    os_lrhaz_plt_llog 
    os_lrhaz_plt_lnor 
    os_lrhaz_plt_gamm 
    os_lrhaz_plt_gomp 
    os_lrhaz_plt_nphw  
  ] 
  ex1_raw_os.pdf 
  [ 
    os_km_raw 
    os_lr_raw_expo 
    os_lr_raw_weib 
    os_lr_raw_lnor 
    os_lr_raw_gamm 
    os_lr_raw_llog 
  ] 
  
  ex1_all_os.xls 
  [ 
    os_km_pl 
    os_lr_inf 
    os_lrkm_pl_est 
    os_lr_est 
    os_lr_est_expo 
    os_lr_est_weib 
    os_lr_est_llog 
    os_lr_est_gamm 
    os_lr_est_lnor 
  ] 
  ex1_raw_dfs.xls 
  [ 
    os_km_raw 
    os_lr_raw_expo 
    os_lr_raw_weib 
    os_lr_raw_lnor 
    os_lr_raw_gamm 
    os_lr_raw_llog 
  ] 
); 
quit; 
 
%mend stem_macro; 
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